Dapagliflozin with insulin for patients with Type 1 Diabetes

11th October 2019 by Louise Hudman

Dapagliflozin with insulin for patients with Type 1 Diabetes

This is a new guideline from NICE on using dapagliflozin in patients with Type 1 diabetes. It was published in Aug 19.

Key learning points for me:

  • There is a rise in the risk of ketoacidosis.
  • It needs stopping if there is a sustained fall in GFR to < 45.

The main concern with using dapagliflozin alongside insulin in patients with Type 1 diabetes (T1DM) is that there is an almost two-fold rise in the risk of diabetic ketoacidosis. However the absolute risk is not that high. Because of this, quite rigid restrictions have been placed on who is eligible.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"The quality and contents of the magazine are superb. It's wonderful that GP locums now have a voice and are seen as a vital part of the medical workforce."

Dr Irene Bainbridge

See the full list of features within our NASGP membership plans

Membership